Shanghai Qilu Pharmaceutical presents new PARP-7 inhibitors for cancer
Feb. 23, 2023
Shanghai Qilu Pharmaceutical Research and Development Centre Ltd. has divulged protein mono-ADP-ribosyltransferase TIPARP (PARP-7; ARTD14) inhibitors reported to be useful for the treatment of cancer.